Associate Director, Commercial Analytics & Operations at Corcept Therapeutics

Redwood City, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, OncologyIndustries

Requirements

Demonstrated success in leading commercial analytics across marketing, market access and omnichannel execution

Responsibilities

Lead HQ launch tracking for Relacorilant, developing and maintaining KPIs and dashboards to monitor launch performance, market penetration and key business metrics
Establish robust tracking processes and provide regular updates and recommendations to senior leadership to inform decision making
Act as a strategic partner to Marketing, Market Access, Sales, and Commercial Operations teams, ensuring analytical insights are translated into actionable strategies
Lead the development and management of predictive alerts systems that leverage advanced analytics to identify physicians and patients requiring timely intervention, delivering actionable alerts to field teams and marketing activation platforms to optimize engagement timing and personalization strategies
Deliver insights into the patient journey, including demographics, treatment dynamics and market access landscape
Operationalize the patient longitudinal claims framework to provide analysis of treatment transitions, persistence, compliance, payer mix, rejections/reversals and out-of-pocket trends
Uphold Corcept’s Key Principles by driving collaboration, embracing possibilities, following the data, and leading by doing, ensuring all initiatives align with the Company’s ethics and patient-first principles
Drive measurement of reach, engagement, and impact of marketing campaigns across all channels and touchpoints
Lead Marketing Mix Modeling (MMM) initiatives to quantify marketing ROI and optimize media investment allocation across traditional and digital channels
Collaborate with marketing to build and enhance customer journey mappings by segment within Salesforce Marketing Cloud and orchestration capabilities across personal and non-personal channels
Leverage insights from analytics to design and activate automated omnichannel campaigns that optimize engagement timing, channel selection and impact with patients and healthcare providers
Lead managed care analytics to generate insights on payer coverage, formulary positioning and access dynamics for Relacorilant
Track payer trends and access barriers, recommending strategies to improve patient affordability and access
Analyze specialty pharmacy, hub services and claims data
Develop dashboards tracking managed care landscape, SP/SD channel performance, SP/Hub Patient Journey and Patient Services Hub

Skills

Commercial Analytics

KPIs

Dashboards

Predictive Analytics

Advanced Analytics

Market Penetration

Business Metrics

Strategic Reporting

Data Visualization

Launch Tracking

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free